[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619332":3},{"organization":4,"outcomesModule":7,"designInfo":15,"detailedDescription":11,"studyPopulation":11,"armGroups":21,"interventions":45,"overallOfficials":11,"centralContacts":11,"locations":61,"responsibleParty":78,"collaborators":11,"id":80,"slug":11,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":11,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Cmax,ss",null,"Baseline to Day 13 or Day 15",{"measure":14,"description":11,"timeFrame":12},"AUCτ,ss",{"allocation":16,"interventionModel":17,"interventionModelDescription":11,"primaryPurpose":18,"observationalModel":11,"timePerspective":11,"maskingInfo":19},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":20,"maskingDescription":11,"whoMasked":11},"NONE",[22,28,31,35,38,42],{"label":23,"type":24,"description":11,"interventionNames":25},"Cohort 1, A","EXPERIMENTAL",[26,27],"Drug: DW4421","Drug: DW4421-N1",{"label":29,"type":24,"description":11,"interventionNames":30},"Cohort 1, B",[26,27],{"label":32,"type":24,"description":11,"interventionNames":33},"Cohort 2, C",[26,34],"Drug: DW4421-N2",{"label":36,"type":24,"description":11,"interventionNames":37},"Cohort 2, D",[26,34],{"label":39,"type":24,"description":11,"interventionNames":40},"Cohort 3, E",[26,41],"Drug: DW4421-N3",{"label":43,"type":24,"description":11,"interventionNames":44},"Cohort 3, F",[26,41],[46,51,55,58],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"DRUG","DW4421","QD",[23,29,32,36,39,43],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"DW4421-N1","BID",[23,29],{"type":47,"name":56,"description":53,"armGroupLabels":57,"otherNames":11},"DW4421-N2",[32,36],{"type":47,"name":59,"description":49,"armGroupLabels":60,"otherNames":11},"DW4421-N3",[39,43],[62],{"facility":63,"status":64,"city":65,"state":11,"zip":11,"country":66,"countryCode":11,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Chungbuk National University Hospital","RECRUITING","Cheongju-si","South Korea",{"type":68,"coordinates":69},"Point",[70,71],127.48972,36.63722,{"lat":71,"lon":70},[74],{"name":63,"role":75,"phone":76,"phoneExt":11,"email":77},"CONTACT","+82-43-269-6771","cbnuhirb@naver.com",{"type":79,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619332",false,"NCT07343245","A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics Drug-Drug Interaction of DW4421 and 3 NSAIDs in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history",true,"ALL","19 Years","50 Years",{"count":91,"type":92},150,"ESTIMATED","INTERVENTIONAL",[95],"PHASE1","Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs",[98],"Healthy Adult","2026-01-06",{"date":101,"type":102},"2026-01-15","ACTUAL",{"date":104,"type":102},"2025-12-01",{"date":106,"type":92},"2026-06-17",{"name":5,"class":6},1]